WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 412346
CAS#: 477-32-7
Description: Visnadine is a natural vasodilator. It was first isolated from bishop's weed, a plant indigenous to the Mediterranean region which has been used for centuries in Egypt as a spasmolytic.
MedKoo Cat#: 412346
Name: Visnadine
CAS#: 477-32-7
Chemical Formula: C21H24O7
Exact Mass: 388.1522
Molecular Weight: 388.42
Elemental Analysis: C, 64.94; H, 6.23; O, 28.83
Synonym: Visnadine; BRN0055264; BRN-0055264; BRN 0055264
IUPAC/Chemical Name: (9R,10R)-10-acetoxy-8,8-dimethyl-2-oxo-9,10-dihydro-2H,8H-pyrano[2,3-f]chromen-9-yl (R)-2-methylbutanoate
InChi Key: GVBNSPFBYXGREE-CXWAGAITSA-N
InChi Code: InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1
SMILES Code: CC[C@H](C(O[C@@H]1[C@@H](c2c3c(C=CC(O3)=O)ccc2OC1(C)C)OC(C)=O)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 388.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bernorio R, Piloni S, Mori G, Prunas A, Bosoni D, Nappi RE. Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. J Endocrinol Invest. 2018 Jun;41(6):729-737. doi: 10.1007/s40618-017-0801-0. Epub 2017 Dec 11. PMID: 29230716.
2: Caputo A, Natoli A, Radice R, Zanardi G, Giacomelli L. Efficacy of an intimate oil solution containing visnadine in women self-reporting sexual symptoms. Minerva Ginecol. 2018 Aug;70(4):492-493. doi: 10.23736/S0026-4784.18.04209-0. PMID: 29952501.
3: Sparavigna A, Caputo A, Natoli A, Mandelli C. A randomized single-blind placebo-controlled study of a Visnadine Emulgel formulation on healthy postmenopausal women. Minerva Ginecol. 2019 Oct;71(5):353-358. doi: 10.23736/S0026-4784.19.04398-3. PMID: 31698889.
4: Caputo A, Sparavigna A, Natoli A, Mandelli C. An open trial of a Visnadine emulgel topical application in postmenopausal superficial dyspareunia: daily vs. on-demand use. Minerva Ginecol. 2020 Feb;72(1):59-60. doi: 10.23736/S0026-4784.19.04402-2. Epub 2019 Sep 20. PMID: 31560182.
5: Caruso S, Mauro D, Cariola M, Fava V, Rapisarda AMC, Cianci A. Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder. Gynecol Endocrinol. 2018 Feb;34(2):110-114. doi: 10.1080/09513590.2017.1354366. Epub 2017 Jul 27. PMID: 28749253.
6: Laganà AS, Vitale SG, Stojanovska L, Lambrinoudaki I, Apostolopoulos V, Chiofalo B, Rizzo L, Basile F. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas. 2018 Mar;109:78-80. doi: 10.1016/j.maturitas.2017.12.015. Epub 2017 Dec 24. PMID: 29452786.
7: Durate J, Vallejo I, Pérez-Vizcaino F, Jiménez R, Zarzuelo A, Tamargo J. Effects of visnadine on rat isolated vascular smooth muscles. Planta Med. 1997 Jun;63(3):233-6. doi: 10.1055/s-2006-957660. PMID: 9225605.
8: TETREAU H. LA VISNADINE DANS LE TRAITEMENT DE L'INFARCTUS DU MYOCARDE ET DE LA MALADIE CORONARIENNE [VISNADINE IN THE TREATMENT OF MYOCARDIAL INFARCT AND CORONARY DISEASE]. Prog Med (Paris). 1964 Jul 10;92:485-94. French. PMID: 14182038.
9: Kiesewetter E. Koronartherapie mit Visnadin [Coronary treatment with visnadine]. Wien Med Wochenschr. 1969 May 3;119(18):346-7. German. PMID: 4979695.
10: Bargheer R, Fiegel G, Saito S, Guttmann W. Die Wirkung von Visnadin bei chronisch-degenerativen Myocardschäden [The effect of Visnadine in chronic degenerative myocardial lesions]. Arzneimittelforschung. 1967 Mar;17(3):288-90. German. PMID: 5631219.
